Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Bruton’s tyrosine kinase (BTK) is a clinically validated target for B-cell leukemias and lymphomas with FDA-approved small-molecule inhibitors ibrutinib and acalabrutinib. Tirabrutinib (GS-4059/ONO-4059, Gilead Sciences, Inc., Foster City, CA) is a second-generation, potent, selective, irreversible...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:SLAS Discov
मुख्य लेखकों: Yu, Helen, Truong, Hoa, Mitchell, Scott A., Liclican, Albert, Gosink, John J., Li, Wanying, Lin, Julie, Feng, Joy Y., Jürgensmeier, Juliane M., Billin, Andrew, Xu, Ren, Patterson, Scott, Pagratis, Nikos
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: SAGE Publications 2018
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151956/
https://ncbi.nlm.nih.gov/pubmed/30011241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2472555218786165
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन